PROTOCOL NRG-GY018 - ACTIVATION & TEMPORARY CLOSURE
GYNECOLOGIC

Protocol Title:  “A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer” NCI Version Date: 06/14/2019

The protocol will reopen to accrual pending processing of amendment 1.

Documents and the complete activation/temporary closure memo, outlining Investigator requirements and special DTL requirements for this blinded study will be posted to the  CTSU website shortly.

Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse